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Abstract
Background/Aims: Due to the increasing prevalence of risk factors for chronic kidney disease 
(CKD), kidney dysfunction becomes a major public health problem. We investigated the CKD 
prevalence and determined to what extent the variation of risk factors explains the different 
CKD prevalence in Germany. Methods: We analyzed data from 6,054 participants, aged 31 
to 82 years, from the Study of Health in Pomerania (SHIP-1) in Northeast Germany and the 
Cooperative Health Research in the Region of Augsburg (KORA F4) Study in Southern Germany. 
Regional differences in selected percentiles corresponding to the cutpoints for estimated 
glomerular filtration rate (eGFR, <60 ml/min per 1.73 m²) and albumin-to-creatinine ratio 
(ACR, ≥30 mg/g) were tested using quantile regression models that adjusted for CKD risk 
factors. Results: The prevalence of decreased eGFRcreatinine-cystatinC (5.9 vs. 3.1 %, p <0.001) and 
albuminuria (20.2 vs. 8.8 %, p<0.001) were higher in SHIP-1 than in KORA F4. The differential 
distribution of risk factors explained 18-21% of the regional differences of decreased 
eGFRcreatinine-cystatinC and high ACR. Conclusions: The CKD prevalence is higher in Northeast than 
in Southern Germany. Differences in the prevalence of risk factors partly explain the higher 
disease burden of CKD in Northeast than in Southern Germany.
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Introduction
Kidney dysfunction confers an increased risk of all-cause mortality and cardiovascular 
disease and has, due to its increasing prevalence, become a major public health problem 
worldwide [1-3]. Obesity, type 2 diabetes mellitus, and hypertension are major risk factors 
for chronic kidney disease (CKD) [4-6]. Previous studies demonstrated regional differences 
in the prevalence of such risk factors within Germany, with higher levels in East than in West 
Germany [7-10]. Along with demographic changes related to the ageing societies in European 
countries, the rising prevalence of kidney dysfunction and its risk factors underline the role 
of CKD as a major public health problem in Germany.
Traditionally, CKD has been assessed using markers such as estimated glomerular 
filtration rate (eGFR) based on creatinine (eGFRcreatinine <60 ml/min per 1.73 m2) and/or 
albuminuria [albumin-to-creatinine ratio (ACR) ≥30 mg/g] [11]. A potential alternative for 
creatinine as an endogenous glomerular filtration marker is the circulating protein cystatin 
C [12]. In fact, some studies have shown that the serum cystatin C concentration is a more 
sensitive and accurate indicator of early kidney dysfunction than either the serum creatinine 
concentration, eGFRcreatinine or creatinine clearance [13, 14]. According to the newest 
recommendation of the Kidney Disease Improving Global Outcome (KDIGO) 2012 guideline 
[15], the use of the 2009 CKD-EPI creatinine equation, the 2012 CKD-EPI cystatin C, or the 
2012 CKD-EPI creatinine-cystatin C equation, an equation for eGFR based on both creatinine 
and cystatin C, will improve accuracy of eGFR compared to the alternative eGFR equations 
[16-20]. The newer equations represent an advance over currently available equations across 
the range of eGFR and have greater accuracy in subjects with mildly impaired kidney function 
[17]. A recent study showed that the performance of the combined equation for creatinine 
and cystatin C to determine the prevalence of CKD in epidemiological studies is better than 
the eGFR equations based on either of these markers of kidney function alone [17]. However, 
most studies [21-25] assessing the prevalence of kidney dysfunction in different populations 
used only traditional markers and equations to estimate kidney function. 
In the present analyses, we investigated possible regional disparities in the prevalence 
of CKD within Germany using the newest equations to estimate kidney function [15]. We 
used data from two population-based studies: the Study of Health in Pomerania (SHIP) in 
Northeast Germany and the Cooperative Health Research in the Region of Augsburg (KORA) 
in Southern Germany. Moreover, we analyzed to what extent regional differences in risk factor 
burden explain the difference in CKD prevalence in the two study regions. We selected these 
two regions because they have been shown to differ markedly in the distribution of major 





Data from two population-based studies were used. Both studies conformed to the principles of the 
Declaration of Helsinki. All investigations were approved by the local ethics committees and public data 
protection agencies. 
SHIP-1 is the first follow-up examination of the SHIP-0 study, a cross-sectional population-based 
survey conducted in Northeast Germany in the cities of Greifswald and Stralsund as well as in surrounding 
communities between 1997 and 2001 [28]. Out of 4,308 subjects who participated in the SHIP-0 baseline 
study, 3,300 also took part in the 5-year follow-up SHIP-1 examination (2002-2006, follow-up response 
83.6%) [29].
The KORA F4 study is the first follow-up of the KORA S4 study, a cross-sectional population-based 
survey conducted in Southern Germany in the city of Augsburg and in two surrounding counties between 
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1999 and 2001 [30]. Out of 4,261 subjects who participated in the S4 baseline study, 3,080 also took part in 
the 7-year follow-up KORA F4 examination (2006-2008, follow-up response 79.6%).
In order to create a comparable age range between studies, we excluded 258 SHIP-1 participants 
who were outside the age range of 31 to 82 years. We also excluded subjects with missing data on serum 
creatinine (SHIP-1, n = 14; KORA F4, n= 5), serum cystatin C (SHIP-1, n = 14; KORA F4, n= 22), urinary 
albumin or creatinine (SHIP-1, n = 14; KORA F4, n= 29), and with eGFR <15 ml/min per 1.73 m2 (SHIP-
1, n = 3; KORA F4, n= 2). Thus, the final study sample comprised 3,014 participants in SHIP-1 and 3,040 
participants in KORA F4.
Data collection
In both studies, information on socio-demographic variables, smoking habits, alcohol consumption, 
physical activity level, medical history, and medication use was collected by trained and certificated medical 
staff during a standardized personal interview. Educational level was defined as the self-reported highest 
level of school education (<10 years of school, 10 years of school, >10 years of school based on the East 
German three-level school system). Assessment of alcohol intake (in grams per day) was derived from a 
beverage-specific quantity-frequency index that used self-reported data regarding weekday and weekend 
consumption of beer, wine, and spirits [31]. Study participants provided information on whether they had 
ever smoked cigarettes regularly (never, past only, current) [32]. Individuals who participated in leisure 
time physical training during summer or winter for less than one hour per week were classified as being 
physically inactive [33]. Diabetes mellitus was defined as self-report based on the question whether a 
physician had ever diagnosed type 2 diabetes mellitus or whether the subjects took antidiabetic medication 
(Anatomic Therapeutic Chemical {ATC} Classification System code: A10) [28].
In both studies, all participants underwent an extensive standardized physical examination. Based on 
recommendations of the WHO [34], we measured height, body weight, and waist circumference. Body mass 
index (BMI) was calculated as body weight in kilograms divided by the square of body height in meters 
[35]. Waist circumference was measured to the nearest 0.1 cm using an inelastic tape midway between the 
lower rib margin and the iliac crest in the horizontal plane in subjects standing comfortably with weight 
distributed evenly on both feet [36]. Further, waist-to-height ratio was calculated as waist circumference 
divided by height in centimeters. Systolic and diastolic blood pressures were measured three times after 
an initial five-minute rest period on the right arm of seated subjects using a digital blood pressure monitor 
(HEM-705CP, Omron Corporation, Tokyo, Japan). Measurements were separated by three-minute intervals. 
The mean of the second and third measurements was calculated and used for the present analyses. 
Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, 
or use of antihypertensive medication defined by the ATC code (C02L, C03A/B/C/D/E, C07B/C/D, C08G, 
C09BA, C09DA) [37].
Laboratory procedures 
In SHIP-1, blood samples were taken from the cubital vein of non-fasting participants in the supine 
position between 07:00 a.m. and 04:00 p.m. Blood collection and processing was conducted using a 
standardized protocol. Serum aliquots were prepared for immediate analysis in a central laboratory. Serum 
creatinine concentrations were determined with the Jaffé method (Siemens Dimension RxL; Siemens 
Healthcare Medical Diagnostics, Eschborn, Germany). Serum cystatin C concentrations were measured 
by the particle-enhanced immunonephelometry (N Latex Cystatin C kit, Siemens Healthcare Diagnostics, 
Eschborn, Germany) on the Behring BN Prospec nephelometer (Dade Behring, Liederbach, Germany). A 
single spot urine sample was collected from each subject and stored for a maximum duration of two days 
at 6° C. The urinary creatinine concentration (Jaffé-method) was determined on a Hitachi 717 (Roche 
Diagnostics, Mannheim, Germany). The urinary albumin concentration was determined on a Behring 
Nephelometer (Siemens BN albumin; Siemens Healthcare, Marburg, Germany). 
In KORA F4, blood samples were taken from the cubital vein of seated, overnight fasting participants in 
the morning. Internal and external quality controls were performed according to the WHO MONICA Manual 
[38]. Serum creatinine concentrations were determined using an automated Jaffé method (Technicon, SMAC 
autoanalyzer; Tarrytown, New York, USA). Serum cystatin C concentrations were measured by the particle-
enhanced immunonephelometry (N Latex Cystatin C kit, Dade Behring, Marburg, Germany) on the Behring 
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Nephelometer II analyzer (Dade Behring, Marburg, Germany). A single spot urine sample was collected from 
each subject and stored at -80° C until measurement. The urinary creatinine concentration (Jaffé-method) 
was determined on a Cobas Mira (Greiner, Bahlingen, Germany). The urinary albumin concentration was 
measured quantitatively with an immunoturbidimetric test (Tina-quant_ Albumin in urine, Boehringer 
Mannheim, Germany).
Definition of CKD 
According to the recommendation of the KDIGO 2012 guideline [15], CKD was defined as eGFR <60 ml/min per 
1.73 m2 and/or albuminuria (ACR ≥30 mg/g). The eGFR was determined from serum creatinine and cystatin C using 
three different established equations. We estimated the eGFRcreatinine (ml/min per 1.73 m2) using the 2009 CKD-EPI 
creatinine equation:  
where SCr is serum creatinine measured in mg/dl, ĸ is 0.7 for females and 0.9 for males, α is -0.329 
for females and -0.411 for males, min is the minimum of SCr/ĸ or 1, and max is the maximum of SCr/ĸ or 
1 [15]. Before entering serum creatinine concentrations into the eGFR equation, we calibrated the data to 
the National Health and Nutrition Examination Survey III within age – sex groups to obtain values close to 
Cleveland Clinic creatinine [39, 40]. The eGFRcystatinC (ml/min per 1.73 m2) was estimated using the 2012 
CKD-EPI cystatin C equation:
 
where SCysC is serum cystatin C measured in mg/l, min indicates the minimum of SCysC/0.8 or 1, and 
max indicates the maximum of SCysC/0.8 or 1 [15]. We estimated the eGFRcreatinine (ml/min per 1.73 m2) 
using the 2012 CKD-EPI creatinine-cystatin C equation:
   
where SCr is serum creatinine measured in mg/dl, SCysC is serum cystatin C measured in mg/l, ĸ 
is 0.7 for females and 0.9 for males, α is -0.248 for females and -0.207 for males, min(SCr/ĸ, 1) indicates 
the minimum of SCr/ĸ or 1, and max(SCr/ĸ, 1) indicates the maximum of SCr/ĸ or 1; min(SCysC/0.8, 1) 
indicates the minimum of SCysC/0.8 or 1 and max(SCysC/0.8, 1) indicates the maximum of SCysC/0.8 or 1 
[15]. Since all study participants were of European Caucasian descent, the race variable was omitted from 
eGFR equations. 
Statistical analyses
Data are reported as medians (25th and 75th percentile) or means (standard deviation) for 
continuous variables and as percentages for categorical variables. Group comparisons were performed 
using t-test (mean) or Kruskal-Wallis test (median) for continuous variables and Pearson χ2 tests for 
categorical variables. Tests were considered statistically significant at a two-sided p-value <0.05. Correlation 
coefficients between eGFRcreatinine, eGFRcystatinC, and ACR were calculated in SHIP-1 and KORA F4. Differences 
in the age and sex structure between the study regions were accounted for by direct standardization to the 
German standard population (date 31/12/2007). Age- and sex-specific prevalence estimates for CKD were 
calculated, and results for each age stratum were expressed as percentages with a 95% confidence interval 
(95% CI). Age was stratified into the categories 31-82, 31–44, 45–64, and 65–82 years. Additionally, we 
performed sensitivity analyses by excluding participants in SHIP-1 which reported intake of food during the 
last 5 hours.
Factors explaining differences in selected percentiles corresponding to the cut-points of decreased 
eGFRcreatinine-cystatinC (5th percentile, corresponding to 60 ml/min per 1.73 m2) [15] and high ACR (85th percentile, 
corresponding to 30 mg/g) [15] between the study regions were tested using quantile regression models. 
In these regression models, we adjusted for covariables that might explain regional differences in CKD 
prevalence. The first model included age, sex and a variable indicating the study sample (SHIP or KORA). 
The second model added BMI, waist circumference, or waist-to-height ratio. The third model additionally 
included type 2 diabetes mellitus and the fourth model added hypertension. The final model included all 
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covariables of the previous models as well as physical inactivity, education, alcohol intake, and smoking 
status. We calculated the ratio of unadjusted und adjusted quantile regression coefficients:
[41]. Analyses were performed using Stata 11.2 (Stata Corporation, College Station, TX, USA).
Results
Socio-demographic characteristics and CKD risk factors for individuals living in 
Northeast (SHIP-1) and Southern Germany (KORA F4) are displayed in Table 1. BMI, waist 
circumference, and waist-to-height ratio were similar in both populations. The prevalence 
of hypertension and type 2 diabetes mellitus was higher in SHIP-1 than in KORA F4. Figure 
1 shows moderate correlations between eGFRcreatinine and eGFRcystatinC in SHIP-1 and KORA F4. 
The correlation coefficient between eGFRcreatinine-cystatinC and ACR in SHIP-1 and KORA F4 was 
0.023.
Continuous traits of kidney function in SHIP-1 and KORA F4 
In both samples, all four indices of kidney function (eGFRcreatinine, eGFRcystatinC, eGFRcreatinine-
cystatinC, and ACR) decreased with increasing age (Table 2). Median values of eGFRcreatinine were 
Table 1. Baseline characteristics of the SHIP-1 and KORA F4 study populations
 Kidney Blood Press Res 2015;40:231-243
DOI: 10.1159/000368499
Published online: May 04, 2015
© 2015 S. Karger AG, Basel
www.karger.com/kbr 236
Aumann/Baumeister/Rettig et al.: Regional Variation of CKD
ml/min per 1.73 m²] in the overall sample. Additionally, the age-standardized median values 
of eGFRcreatinine-cystatinC were also lower in SHIP-1 [99.5 (84.7; 111.1) ml/min per 1.73 m²] than 
in KORA F4 [105.3 (91.6; 116.4)ml/min per 1.73 m²] in the overall sample. The differences in 
eGFR between SHIP-1 and KORA F4 were consistently present in each age group. In line with 
the observation related to eGFRcystatinC and eGFRcreatinine-cystatinC, the age-standardized median of 
ACR was higher in SHIP-1 than in KORA F4 in the overall sample and in each age group.
Prevalence of decreased eGFR and albuminuria in SHIP-1 and KORA F4
Table 3 provides the prevalence of the binary trait decreased eGFR, based on a 
combination of creatinine and cystatin C, and albuminuria in SHIP-1 and KORA F4. Consistent 
with the continuous trait analyses mentioned above, the prevalence of decreased eGFRcreatinine-
cystatinC and the prevalence of albuminuria as well as the prevalence of the combination of 
both endpoints were significantly higher in SHIP-1 than in KORA F4. Sensitivity analyses 
after excluding subjects in SHIP-1 with food during the last 5 hours showed almost identical 
estimates of renal function (data not shown). Thus, we can exclude the possibility that regional 
differences of decreased eGFRcreatinine-cystatinC and high ACR might result from differences in 
fasting status at the time of blood withdrawal for laboratory measurements. 
Adjustment for covariables to explain regional differences in eGFRcystatinC and ACR 
Differences in decreased eGFRcreatinine-cystatinC values (5th percentile, corresponding to 60 
ml/min per 1.73 m2) and in high ACR (85th percentile, corresponding to 30 mg/g) between 
SHIP-1 and KORA F4 are displayed in Table 4. Age, sex, BMI (or waist circumference, or waist-
to-height ratio), type 2 diabetes mellitus, and hypertension cumulatively explained 5.6%, 
and the fully adjusted model cumulatively explained 18.0% of the difference in decreased 
eGFRcreatinine-cystatinC values between SHIP-1 and KORA F4. With respect to high ACR, the above 
mentioned risk factors cumulatively explained 20.6% of the difference between SHIP-1 and 
KORA F4.
Discussion 
In the present study, we observed a higher prevalence of CKD in Northeast than in 
South Germany. The difference in decreased eGFRcreatinine-cystatinC values and high ACR is in part 
Fig. 1. Correlation between eGFRcreatinine and eGFRcystatinC in SHIP-1 and 
KORA F4. 
similar in SHIP-1 and 
KORA F4, whereas 
the two populations 
differed from each 
other with respect 
to median values of 
eGFRcystatinC, combined 
eGFRcreatinine-cystatinC, and 
ACR, which provides 
some evidence 
of lower kidney 
function in SHIP-1. 
Specifically, the age-
standardized median 
values of eGFRcystatinC 
were lower in SHIP-1 
[104.7 (84.6; 116.5) 
ml/min per 1.73 
m²] than in KORA F4 
[114.2 (102.5; 123.0) 
 Kidney Blood Press Res 2015;40:231-243
DOI: 10.1159/000368499
Published online: May 04, 2015
© 2015 S. Karger AG, Basel
www.karger.com/kbr 237









































































(to about 18% to 21%) explained by 
regional disparities in the prevalence 
of major CKD risk factors. 
 Kidney Blood Press Res 2015;40:231-243
DOI: 10.1159/000368499
Published online: May 04, 2015
© 2015 S. Karger AG, Basel
www.karger.com/kbr 238
Aumann/Baumeister/Rettig et al.: Regional Variation of CKD
In recent years the prevalence of CKD and the number of patients with kidney failure 
treated by dialysis and transplantation increased dramatically worldwide [2, 3]. It is well 
established that CKD is strongly associated with an increased risk of cardiovascular morbidity 
and mortality [1, 2]. In individuals with early stages of CKD, the risk of cardiovascular 
morbidity and mortality is higher than the risk of progression to kidney failure. Therefore, 
cardiovascular risk factor management is critical in this group [42]. 
The increase in the prevalence of CKD worldwide might be partly explained by the 
increase in the prevalence of major risk factors for CKD including obesity, type 2 diabetes 
mellitus, and hypertension [5, 6, 22]. Ageing of societies is likewise a contributing factor to 
increasing CKD prevalence. In the United States, approximately 17% of persons older than 
60 years of age have a eGFRcreatinine of less than 60 ml/min per 1.73 m2 and the prevalence of 
low eGFRcreatinine increases from 2.9% among adults with an ideal weight (BMI 18.5–24.9 kg/
m2) to 4.5% among obese adults (BMI ≥30 kg/m2) [5]. 
The increase in the proportion of individuals with obesity, type 2 diabetes mellitus, 
and hypertension and the association of kidney dysfunction with cardiovascular disease 
lead to a large public health problem regarding CKD in Germany [1, 2]. Previous studies 
demonstrate regional disparities in the prevalence of established CKD risk factors including 
obesity, type 2 diabetes mellitus, and hypertension with higher levels in East compared to 
West Germany [7-10]. In the present analysis, we demonstrate that the higher prevalence 
of CKD in Northeast Germany is partially explained by the above mentioned differences in 
major risk factors for CKD including hypertension and type 2 diabetes mellitus. Specifically, 
adjustment for all major risk factors explained 21% of the regional variation in high ACR, 
but only 18% of the regional variation in decreased eGFRcreatinine-cystatinC values (Table 4). The 
difference in the predictive value of major CKD risk factors for the two endpoints decreased 
eGFRcreatinine-cystatinC values and high ACR, is partly explained by the stronger association of 
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type 2 diabetes mellitus with albuminuria than with low eGFR [22]. Additionally, obesity 
may cause glomerular hyperfiltration, increased urinary albumin excretion and progressive 
loss of kidney function [43, 44]. Despite its increasing prevalence, obesity may be the most 
important potentially preventable risk factor for CKD due to its strong link with type 2 
diabetes mellitus and hypertension, the two major causes of CKD [5]. Furthermore, our 
data are consistent with the notion that life style risk factors including smoking, alcohol 
consumption, and physical inactivity increase the prevalence of CKD, albeit the effects of 
these factors on kidney function are less important than those of hypertension or type 2 
diabetes mellitus [45-47]. However, adjustment for all risk factors explained only a fraction 
(by up to 21%) of the regional variation in decreased eGFRcreatinine-cystatinC values and high ACR. 
A possible explanation could be that CKD and complications of decreased kidney function 
may be associated with other CKD related risk factors including a family history of kidney 
disease, cardiovascular disease, hemodynamic and metabolic abnormalities that were not 
taken into consideration in this study [48-50].
CKD has been estimated based on a decreased eGFRcreatinine and/or albuminuria [11]. 
However, the serum creatinine concentration is not only determined by the tubular secretion 
of creatinine, but also by the production of creatinine in muscular tissue, which depends on 
age, weight, gender, and muscle mass [51]. The large variety of non-renal influences leads to 
a wide reference range for the serum creatinine concentration [52]. Therefore, we calibrated 
our serum creatinine data to the National Health and Nutrition Examination Survey III 
within age – sex groups to obtain values close to Cleveland Clinic creatinine [39, 53]. Then, 
we used the CKD-EPI creatinine equation that more precisely estimates the eGFR in the 
range of  60 – 90 ml/min per 1.73 m2 than other eGFR equations, such as the widely used 
Modification of Diet in Renal Disease (MDRD) formula [19]. By achieving a greater accuracy 
in subjects with mildly impaired kidney function, the CKD-EPI equation also reduces the 
rate of false positive diagnoses of CKD by GFR category G3a (defined as eGFR <60 ml/min 
per 1.73 m2) [19]. However, there are several limitations to the use of eGFR equations based 
on serum creatinine. There are reasons to believe that both equations overestimate the 
prevalence of CKD because they underestimate the GFR [16]. In contrast to serum creatinine, 
serum cystatin C concentration is less influenced by age, race, and muscle mass [14, 20]. 
The eGFRcystatinC might therefore be a more sensitive and accurate indicator of early kidney 
dysfunction than eGFRcreatinine [14, 20, 54]. Yet, BMI, diabetes, and inflammation may affect 
serum cystatin C concentration independent of kidney function [55]. However, the combined 
equation for creatinine and cystatin C provides more precise GFR estimates than equations 
based on either of these markers alone [17, 20].
Strengths and limitations
Strengths of the present analyses include the large sample size, the population-based 
approach, and the comparable study design of KORA and SHIP, including the high degree 
of standardization in measuring covariates and markers of kidney function. On the other 
hand, several limitations should be considered. In the present study we cannot exclude the 
possibility of bias produced by acute kidney injury because we did not measure acute kidney 
injury. Further, albuminuria was measured using the urinary albumin-to-creatinine ratio from 
a spot urine sample and not by obtaining 24-h urine collections, which are time consuming 
and hard to perform in a population-based study. Several studies reported good correlations 
between the ACR measured in 24-h urine collections and the ACR measured in spot urine 
samples [56, 57]. Another limitation is that different assays were used for measurements 
of urinary albumin in both studies. In SHIP-1, the urinary albumin concentration was 
determined with a nephelometric assay, whereas in KORA F4 it was measured quantitatively 
with an immunoturbidimetric test. Yet, both immunological methods have been developed 
to detect minimal amounts of albumin. In a comparative study, Kleine and Merten obtained 
similar results with both techniques [58]. Further, cystatin C was measured on the Behring 
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Nephelometer II (Dade Behring) in KORA F4 and the BN Prospec Nephelometer (Siemens 
Healthcare Diagnostics) in SHIP-1. The BN Prospec Nephelometer is the successor model of 
the Nephelometer II. As the reagents used for the cystatin C measurement are similar, it is 
reasonable to assume that the measurements are comparable. However, a direct comparison 
between the two analyzers was not available, thus, we are not able to fully exclude or correct 
for possible small measurement differences. Our study is further limited by the lack of direct 
measurements of kidney function such as inulin clearance. For obvious reasons, such invasive 
measurements are not suitable in a population-based study. No “gold standard” diagnosis of 
kidney dysfunction was available, but we calibrated serum creatinine data to the National 
Health and Nutrition Examination Survey III within age – sex groups to obtain values close 
to Cleveland Clinic creatinine [39, 53]. In addition, food intake could bias measurements of 
renal function, especially intake of cooked meat may affect serum creatinine concentration 
and eGFR [59, 60]. Sensitivity analyses after excluding subjects in SHIP-1 with food during the 
last 5 hours (data not shown) exclude the possibility that regional differences of decreased 
eGFRcreatinine-cystatinC and high ACR might result from differences in fasting status between the 
two study populations during blood withdrawal for laboratory measurements.
Conclusion
In conclusion, the differences in the local prevalence of relevant risk factors for kidney 
dysfunction can partly explain the higher disease burden of CKD in Northeast Germany 
compared to Southern Germany. Further studies are needed to investigate the influence of 
other CKD related risk factors. Strong and effective prevention, detection, and treatment of 
risk factors for kidney dysfunction may reduce the risk for development of CKD.
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